Johnson & Johnson Raises Outlook as MedTech Sales Miss, Shares Slide
Johnson & Johnson reported better-than-expected profit and raised its full-year outlook, while MedTech sales of $8.64 billion came in below the $8.71 billion analyst estimate. Shares fell 5.73% to $248.61.
S. indices ended Tuesday lower. 38. The following stocks drew retail traders’ and investors’ attention during the session.
85. 22. 73 in after-hours trading. S.
21 billion. The penalties include a record Treasury enforcement package related to anti-money laundering and sanctions violations. Johnson & Johnson (NYSE: JNJ) remained under pressure Tuesday despite reporting better-than-expected profit and raising its full-year outlook. 17.
07. Johnson & Johnson exceeded profit expectations and lifted its full-year outlook, while MedTech sales came in below analyst estimates. 71 billion estimate. 36 per share in 2027.
That contributed to an approximately 6% decline in the stock, its steepest drop in more than 18 months. 26. 80, respectively. Shares dropped to seven-year lows after a 42-year-old man died following an apparent ejection from the Goliath roller coaster at the company’s Georgia theme park.
The incident led to ride closures and an investigation. The death also added uncertainty to Jana Partners’ renewed effort to sell the company. Potential legal liabilities could complicate a transaction, after the activist investor had previously won leadership changes and advocated asset sales. Citigroup Inc.
53. 50, and its low was not provided in the source section. 96. 85 per share.
Revenue climbed 8% year over year to its highest third-quarter level in a decade, led by 15% growth in Services and 6% gains in both Markets and Banking. Expenses increased just 3%, supporting positive operating leverage. 8% CET1 capital ratio. Applied Materials Inc.
81. 67. The company forecast AI-driven growth in semiconductor equipment spending through 2030. 42 in fiscal 2025.
The shares have declined roughly 15% since Oct. 5 amid weakness across the semiconductor sector. Cantor Fitzgerald kept its Overweight rating and $850 price target, saying concerns about memory oversupply were overstated and The company’s long-term earnings potential remained strong. Edge rankings put Bank of America’s Momentum score in the 48th percentile and its Growth score in the 76th percentile.